Key statistics dashboard for InflaRx N.V. (IFRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases.
Stock Data
| Price | $2.04 |
| Market Cap | $300M |
| Enterprise Value | $116.4M |
| Beta | 1.51 |
| Exchange | NASDAQ |
| Country | DE |
Valuation Multiples
| P/E Ratio | -3.58 |
| Price / Book | 1.41 |
| P/S | -25508.60 |
| EV/EBITDA | -3.00 |
| EV/Sales | -11523.80 |
| EV/FCF | -4.86 |
| P/FCF | -10.75 |
| Earnings Yield | -18.70% |
| FCF Yield | -9.14% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 48201.61% |
| EBIT Margin | 386804.11% |
| EBITDA Margin | 384053.25% |
| Operating Margin | 362271.47% |
| Net Margin | 387532.08% |
| Return on Equity | -58.00% |
| Return on Assets | -23.46% |
| Return on Invested Capital | -24.89% |
| Return on Capital Employed | -24.94% |
Financial Health
| Current Ratio | 8.22 |
| Quick Ratio | 8.22 |
| Cash Ratio | 7.28 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.50% |
| Net Debt / EBITDA | 3.76 |
| Interest Coverage | -610.45 |
Per-Share Data
| Revenue per share | -0.00 |
| Book Value per share | 1.24 |
| Cash per share | 1.35 |
| FCF per share | -0.20 |
| Tangible Book Value per share | 1.24 |
| Dividend per share | 0.00 |
Related companies: ARTV · ATYR · CNTB · CNTX · IMA · KLRS · MGX
Explore sector: Healthcare · Biotechnology
More sections of IFRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks